DENTSPLY SIRONA Inc.

Fundamentals5.0
Price Action6.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Strong gross margin
  • High leverage
  • Positive free cash

AI
AI Summary

5.0

XRAY is no longer a dividend/yield story but a high-leverage, execution-dependent turnaround after management cut the dividend and redirected capital to a $120M restructuring plus debt reduction/buybacks, so the stock only merits upside if the company delivers sequential net-debt declines and durable operating cash-flow conversion. Monitor quarterly OCF after restructuring, net leverage (quarter-over-quarter), and margin recovery—if those metrics don't show clear improvement, buybacks or product wins (e.g., dental MRI) will not re-rate the equity.

Deleveraging
ExecutionRisk
DentalMRI‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Strong gross margin
  • High leverage
  • Positive free cash

XRAY has strong gross margins and positive free cash flow but is weighed down by recurring operating/net losses and very high leverage that create a material solvency risk.

LeverageRisk
PotentialValue

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Downtrend intact
  • Former support = resistance
  • Near last month low

XRAY is in a clear downtrend from last month's high ($14.68) to the recent low ($10.95), trading below prior short-term support ($11.50–$12.80) which now acts as resistance, with a short-term oversold condition that could prompt a bounce but would confirm more bearish momentum if $10.95 breaks on rising volume.

bearish
oversold
Support Level: $10.95
Resistance Level: $11.50–$12.80

Price fell from last month's high $14.68 to $10.95, leaving

Sentiment & News

6.0

Key News Insights:

  • Restructuring & cuts
  • FDA dental MRI
  • Volatile share reaction

Dentsply Sirona reported mixed Q4 results—sales +6.2% but a $146M loss after impairments—launched a $120M restructuring, cut its dividend to prioritize debt reduction and buybacks, won FDA clearance for a dental MRI, and faced investor scrutiny amid volatile stock moves.

loss

The moves should improve balance-sheet focus and strategic growth potential but near-term earnings volatility and governance scrutiny likely keep pressure on the stock